Amgen UK’s first-in-class medicine sotorasib (a targeted KRAS G12C inhibitor formerly named AMG 510) has become the first new cancer therapy to receive Conditional Marketing Authorisation for use1 across England, Scotland and Wales by the Medicines and Healthcare products Regulatory Agency (MHRA) under Project Orbis. This authorisation follows a review of sotorasib’s role in treating patients with previously treated locally advanced or metastatic non-small […]
Menu ≡ ╳ 
